Research article summary (published 30 Oct 2009):

Intravitreal ranibizumab as primary treatment for neovascular membrane associated with idiopathic juxtafoveal retinal telangiectasia.

Full Abstract

No abstract is available for this article. See 'Journal and Publication Information' further down the page for details that may assist you in locating this article in electronic or hard copy media. The 'Related articles' section also further down the page, where available, may show links to abstracts of articles covering similar topics.

Author information

Author/s: Konstantinidis, Lazaros (L); Mantel, Irmela (I); Zografos, Leonidas (L); Ambresin, Aude (A);

Journal and publication information

Publication Type: Case Reports; Letter

Journal: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie (Graefes Arch Clin Exp Ophthalmol), published in Germany. (Language: eng)

Reference: 2009-Nov; vol 247 (issue 11) : pp 1567-9

Dates: Created 2009/10/08; Completed 2009/11/04;

PMID: 19727795, status: MEDLINE (last retrieval date: 11/4/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal - therapeutic use Female Fluorescein Angiography Follow-Up Studies Humans Injections Middle Aged

Middle Aged Retinal Neovascularization - diagnosis; drug therapy Retinal Vessels - pathology Retreatment Telangiectasis - diagnosis; drug therapy Tomography, Optical Coherence Visual Acuity Vitreous Body

Associated Chemicals: Angiogenesis Inhibitors (0) ; Antibodies, Monoclonal (0) ; ranibizumab (0)

Related articles

These are the highest related articles currently in the database:

• Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia. 6 Mar 2007
• Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. 27 Nov 2006
• Management of Coats disease with bevacizumab in 2 patients. 30 Mar 2008
• Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for subretinal neovascular membrane (SRNVM) associated with type 2 idiopathic macular telangiectasia. 10 Jan 2008
• Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation. 15 Apr 2007
• Bevacizumab in the treatment of idiopathic macular telangiectasia. 31 Mar 2008
• Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal neovascularization. 29 Sep 2006
• Combined intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation. 21 Aug 2008
• Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). 30 Oct 2006
• Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy. 29 Nov 2006

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.